Skip to main content

Urology

Labcorp is dedicated to urology testing, providing comprehensive diagnostic services to support the detection and management of urological conditions. Our laboratory offers a range of tests, including prostate cancer screening, which utilizes advanced biomarkers to identify early signs of prostate malignancy. In addition to performing routine screening, we excel in hereditary cancer diagnostics, employing genetic testing to assess an individual's risk of developing urological cancers based on their family history and genetic predisposition. Our lab also offers a range of companion diagnostics, which are crucial for personalizing treatment plans by identifying which patients are most likely to benefit from specific associated therapies. This tailored approach enables effective and targeted treatment, enhancing patient outcomes in urological health.

Prostate Health Index (phi) is now available.

Discover how phi can guide better prostate cancer detection and management.

Featured urology tests

Prostate Health Index (phi)

phi is designed to aid in distinguishing prostate cancer from benign prostatic conditions in patients aged 50 years and older with total PSA ≥4.0 to ≤10.0 ng/mL with digital rectal examination findings that are not suspicious for cancer

View Test

VistaSeq®

VistaSeq® Prostate Panel assay is intended for patients with a personal history of prostate cancer or a family history consistent with an inherited cancer syndrome. In addition, the National Comprehensive Cancer Network (NCCN) Guidelines recommend that patients diagnosed with Grade Group (GG) 1-3 prostate cancers and a suspicious family history should undergo germline testing, and those with GG4 and 5 prostate cancers should be tested as well (source Prostate Cancer. NCCN Guidelines for Patients®, Version 2.2021)

View Test

OmniSeq® INSIGHT

NGS-based genomic and immune profiling assay including RNA-seq, TMB, MSI, and PD-L1 IHC. Comprehensive genomic and immune profiling gives a complete picture of a patient's tumor and details specific treatment options in one easy to-interpret report

View Test